StockData

Aquestive Therapeutics vs Alpha Teknova

AQST and TKNO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AQST and TKNO compare

Aquestive Therapeutics and Alpha Teknova are about the same size, with market caps of $464M and $411M.

Aquestive Therapeutics grew revenue faster over the last twelve months (22.6% versus 12.3% for Alpha Teknova).

Alpha Teknova keeps more of each dollar of sales as profit, with a net margin of −38.4% compared with −145% at Aquestive Therapeutics.

Alpha Teknova scores higher on the StockData Score (12 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAQSTTKNO
Size and price
Market cap$464M$411M
Share price$3.70$7.65
Change, 1 year−31.4%71.9%
Change, 5 years−41.9%−63.5%
Beta (5Y)1.202.37
Employees147158
StockData Score
Total score312 (better)
Valuation score00
Growth score23 (better)
Performance score03 (better)
Health score16 (better)
Dividend score00
Valuation
P/S8.6× (better)9.4×
P/B–6.6×
FCF yield−9.9%−1.8% (better)
Fair value–$3.42
Margin of safety–−124%
Growth
Revenue growth (TTM)22.6% (better)12.3%
Revenue growth, 5Y average−0.58%5.3% (better)
Profitability
Gross margin67.0% (better)34.6%
Operating margin−97.5%−36.2% (better)
Net margin−145%−38.4% (better)
FCF margin−85.0%−16.8% (better)
Return on equity–−24.2%
Return on invested capital–−25.7%
Financial health
Debt / equity–0.00
Interest coverage−4.7×–
Current ratio7.19 (better)4.49
Altman Z-score−3.575.52 (better)
Piotroski F-score26 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions57.4%17.0%
Held by insiders3.2%1.3%
Insider net buying, 12 months−$2.3M$144K (better)
Short interest, % of float24.1%2.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.